TY  - JOUR
AU  - Ceulemans, Michael
AU  - Lupattelli, Angela
AU  - Nordeng, Hedvig
AU  - Odalović, Marina
AU  - Twigg, Michael J.
AU  - Foulon, Veerle
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3348
AB  - Background: During pregnancy, women might weigh the benefits of treatment against potential risks to the unborn child. However, non-adherence to necessary treatment can adversely affect both mother and child. To optimize pregnant women's beliefs and medication adherence, community pharmacists are ideally positioned to play an important role in primary care. Objective: This narrative review aimed to summarize the evidence on 1) pregnant women's beliefs, 2) medication adherence in pregnancy and 3) community pharmacists' counselling during pregnancy. Methods: Three search strategies were used in Medline and Embase to find original studies evaluating women's beliefs, medication adherence and community pharmacists' counselling during pregnancy. All original descriptive and analytic epidemiological studies performed in Europe, North America and Australia, written in English and published from 2000 onwards were included. Results: We included 14 studies reporting on women's beliefs, 11 studies on medication adherence and 9 on community pharmacists' counselling during pregnancy. Women are more reluctant to use medicines during pregnancy and tend to overestimate the teratogenic risk of medicines. The risk perception varies with the type of medicine, level of health literacy, education level and occupation. Furthermore, low medication adherence during pregnancy is common. Finally, limited evidence showed that the current community pharmacists' counselling is insufficient. Barriers hindering pharmacists are insufficient knowledge and limited access to reliable information. Conclusion: Concerns about medication use and non-adherence are widespread among pregnant women. Community pharmacists' counselling during pregnancy is insufficient. Further education, training and research are required to support community pharmacists in fulfilling all the opportunities they have when counselling pregnant women.
PB  - Bentham Science Publ Ltd, Sharjah
T2  - Current Pharmaceutical Design
T1  - Women's Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists
VL  - 25
IS  - 5
SP  - 469
EP  - 482
DO  - 10.2174/1381612825666190321110420
ER  - 

@article{
author = "Ceulemans, Michael and Lupattelli, Angela and Nordeng, Hedvig and Odalović, Marina and Twigg, Michael J. and Foulon, Veerle",
year = "2019",
abstract = "Background: During pregnancy, women might weigh the benefits of treatment against potential risks to the unborn child. However, non-adherence to necessary treatment can adversely affect both mother and child. To optimize pregnant women's beliefs and medication adherence, community pharmacists are ideally positioned to play an important role in primary care. Objective: This narrative review aimed to summarize the evidence on 1) pregnant women's beliefs, 2) medication adherence in pregnancy and 3) community pharmacists' counselling during pregnancy. Methods: Three search strategies were used in Medline and Embase to find original studies evaluating women's beliefs, medication adherence and community pharmacists' counselling during pregnancy. All original descriptive and analytic epidemiological studies performed in Europe, North America and Australia, written in English and published from 2000 onwards were included. Results: We included 14 studies reporting on women's beliefs, 11 studies on medication adherence and 9 on community pharmacists' counselling during pregnancy. Women are more reluctant to use medicines during pregnancy and tend to overestimate the teratogenic risk of medicines. The risk perception varies with the type of medicine, level of health literacy, education level and occupation. Furthermore, low medication adherence during pregnancy is common. Finally, limited evidence showed that the current community pharmacists' counselling is insufficient. Barriers hindering pharmacists are insufficient knowledge and limited access to reliable information. Conclusion: Concerns about medication use and non-adherence are widespread among pregnant women. Community pharmacists' counselling during pregnancy is insufficient. Further education, training and research are required to support community pharmacists in fulfilling all the opportunities they have when counselling pregnant women.",
publisher = "Bentham Science Publ Ltd, Sharjah",
journal = "Current Pharmaceutical Design",
title = "Women's Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists",
volume = "25",
number = "5",
pages = "469-482",
doi = "10.2174/1381612825666190321110420"
}

Ceulemans, M., Lupattelli, A., Nordeng, H., Odalović, M., Twigg, M. J.,& Foulon, V.. (2019). Women's Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists. in Current Pharmaceutical Design
Bentham Science Publ Ltd, Sharjah., 25(5), 469-482.
https://doi.org/10.2174/1381612825666190321110420

Ceulemans M, Lupattelli A, Nordeng H, Odalović M, Twigg MJ, Foulon V. Women's Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists. in Current Pharmaceutical Design. 2019;25(5):469-482.
doi:10.2174/1381612825666190321110420 .

Ceulemans, Michael, Lupattelli, Angela, Nordeng, Hedvig, Odalović, Marina, Twigg, Michael J., Foulon, Veerle, "Women's Beliefs About Medicines and Adherence to Pharmacotherapy in Pregnancy: Opportunities for Community Pharmacists" in Current Pharmaceutical Design, 25, no. 5 (2019):469-482,
https://doi.org/10.2174/1381612825666190321110420 . .

TY  - JOUR
AU  - Lupattelli, Angela
AU  - Twigg, Michael J.
AU  - Zagorodnikova, Ksenia
AU  - Moretti, Myla E.
AU  - Drozd, Mariola
AU  - Panchaud, Alice
AU  - Rieutord, Andre
AU  - Juraski, Romana Gjergja
AU  - Odalović, Marina
AU  - Kennedy, Debra
AU  - Rudolf, Gorazd
AU  - Juch, Herbert
AU  - Nordeng, Hedvig
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3227
AB  - Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.
PB  - Dove Medical Press Ltd, Albany
T2  - Clinical Epidemiology
T1  - Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale
VL  - 10
SP  - 655
EP  - 669
DO  - 10.2147/CLEP.S156210
ER  - 

@article{
author = "Lupattelli, Angela and Twigg, Michael J. and Zagorodnikova, Ksenia and Moretti, Myla E. and Drozd, Mariola and Panchaud, Alice and Rieutord, Andre and Juraski, Romana Gjergja and Odalović, Marina and Kennedy, Debra and Rudolf, Gorazd and Juch, Herbert and Nordeng, Hedvig",
year = "2018",
abstract = "Purpose: This study aimed at exploring the prevalence of self-reported antenatal and postnatal depressive symptoms by severity across multiple countries and the association between antidepressant treatment in pregnancy and postnatal symptom severity. Materials and methods: This was a multinational web-based study conducted across 12 European countries (n=8069). Uniform data collection was ensured via an electronic questionnaire. Pregnant women at any gestational week and mothers of children with  lt 1 year of age could participate. We used the Edinburgh Postnatal Depression Scale (EPDS) to measure the prevalence of antenatal and postnatal depressive symptoms according to severity, which were corrected by survey weight adjustment (descriptive analysis). Within mothers with a psychiatric disorder (n=173), we estimated the association between antidepressant treatment in pregnancy and postnatal depressive symptom severity, as standardized EPDS mean scores, via the inverse probability of treatment weight (association analysis). Results: In the descriptive analysis (n=8069), the period prevalence of moderate-to-very severe depressive symptoms was higher in the western and eastern regions relative to the northern region, both in the antenatal period (6.8%-7.5% vs 4.3%) and in the postnatal period (7.6% vs 4.7%). One in two mothers with psychiatric disorders used an antidepressant in pregnancy (86 of 173). In the association analysis, women medicated at any time during pregnancy (adjusted beta=-0.34, 95% confidence interval [CI] =-0.66, -0.02) had a significant postnatal symptom severity reduction compared with the nonmedicated counterpart. This effect was larger (beta=-0.74, 95% CI =-1.24, -0.24) when the analysis was restricted to mothers within 6 months after childbirth. Conclusion: The prevalence of self-reported antenatal and postnatal depressive symptoms differs across European countries. Among women with psychiatric disorders, those who had been on treatment with antidepressants during pregnancy were less likely to report postnatal depressive symptoms, particularly within the 6-month period after childbirth, compared with the nonmedicated counterpart.",
publisher = "Dove Medical Press Ltd, Albany",
journal = "Clinical Epidemiology",
title = "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale",
volume = "10",
pages = "655-669",
doi = "10.2147/CLEP.S156210"
}

Lupattelli, A., Twigg, M. J., Zagorodnikova, K., Moretti, M. E., Drozd, M., Panchaud, A., Rieutord, A., Juraski, R. G., Odalović, M., Kennedy, D., Rudolf, G., Juch, H.,& Nordeng, H.. (2018). Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology
Dove Medical Press Ltd, Albany., 10, 655-669.
https://doi.org/10.2147/CLEP.S156210

Lupattelli A, Twigg MJ, Zagorodnikova K, Moretti ME, Drozd M, Panchaud A, Rieutord A, Juraski RG, Odalović M, Kennedy D, Rudolf G, Juch H, Nordeng H. Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale. in Clinical Epidemiology. 2018;10:655-669.
doi:10.2147/CLEP.S156210 .

Lupattelli, Angela, Twigg, Michael J., Zagorodnikova, Ksenia, Moretti, Myla E., Drozd, Mariola, Panchaud, Alice, Rieutord, Andre, Juraski, Romana Gjergja, Odalović, Marina, Kennedy, Debra, Rudolf, Gorazd, Juch, Herbert, Nordeng, Hedvig, "Self-reported perinatal depressive symptoms and postnatal symptom severity after treatment with antidepressants in pregnancy: a cross-sectional study across 12 European countries using the Edinburgh Postnatal Depression Scale" in Clinical Epidemiology, 10 (2018):655-669,
https://doi.org/10.2147/CLEP.S156210 . .

TY  - JOUR
AU  - Lupattelli, Angela
AU  - Spigset, Olav
AU  - Bjoernsdottir, Ingunn
AU  - Haemeen-Anttila, Katri
AU  - Mardby, Ann-Charlotte
AU  - Panchaud, Alice
AU  - Juraski, Romana Gjergja
AU  - Rudolf, Gorazd
AU  - Odalović, Marina
AU  - Drozd, Mariola
AU  - Twigg, Michael J.
AU  - Juch, Herbert
AU  - Moretti, Myla E.
AU  - Kennedy, Debra
AU  - Rieutord, Andre
AU  - Zagorodnikova, Ksenia
AU  - Passier, Anneke
AU  - Nordeng, Hedvig
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2397
AB  - BackgroundNo previous studies have explored how closely women follow their psychotropic drug regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. MethodsMultinational web-based study was performed in 18 countries in Europe, North America, and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women's beliefs, depressive symptoms, and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n = 160) were included in the analysis. ResultsOn the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk6), and depressive symptoms were associated with a significant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r = .282) with higher medication adherence. ConclusionsApproximately one of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms, and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy.
PB  - Wiley, Hoboken
T2  - Depression and Anxiety
T1  - Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study
VL  - 32
IS  - 6
SP  - 426
EP  - 436
DO  - 10.1002/da.22352
ER  - 

@article{
author = "Lupattelli, Angela and Spigset, Olav and Bjoernsdottir, Ingunn and Haemeen-Anttila, Katri and Mardby, Ann-Charlotte and Panchaud, Alice and Juraski, Romana Gjergja and Rudolf, Gorazd and Odalović, Marina and Drozd, Mariola and Twigg, Michael J. and Juch, Herbert and Moretti, Myla E. and Kennedy, Debra and Rieutord, Andre and Zagorodnikova, Ksenia and Passier, Anneke and Nordeng, Hedvig",
year = "2015",
abstract = "BackgroundNo previous studies have explored how closely women follow their psychotropic drug regimens during pregnancy. This study aimed to explore patterns of and factors associated with low adherence to psychotropic medication during pregnancy. MethodsMultinational web-based study was performed in 18 countries in Europe, North America, and Australia. Uniform data collection was ensured via an electronic questionnaire. Pregnant women were eligible to participate. Adherence was measured via the 8-item Morisky Medication Adherence Scale (MMAS-8). The Beliefs about Prescribed Medicines Questionnaire (BMQ-specific), the Edinburgh Postnatal Depression Scale (EPDS), and a numeric rating scale were utilized to measure women's beliefs, depressive symptoms, and antidepressant risk perception, respectively. Participants reporting use of psychotropic medication during pregnancy (n = 160) were included in the analysis. ResultsOn the basis of the MMAS-8, 78 of 160 women (48.8%, 95% CI: 41.1-56.4%) demonstrated low adherence during pregnancy. The rates of low adherence were 51.3% for medication for anxiety, 47.2% for depression, and 42.9% for other psychiatric disorders. Smoking during pregnancy, elevated antidepressant risk perception (risk6), and depressive symptoms were associated with a significant 3.9-, 2.3-, and 2.5-fold increased likelihood of low medication adherence, respectively. Women on psychotropic polytherapy were less likely to demonstrate low adherence. The belief that the benefit of pharmacotherapy outweighed the risks positively correlated (r = .282) with higher medication adherence. ConclusionsApproximately one of two pregnant women using psychotropic medication demonstrated low adherence in pregnancy. Life-style factors, risk perception, depressive symptoms, and individual beliefs are important factors related to adherence to psychotropic medication in pregnancy.",
publisher = "Wiley, Hoboken",
journal = "Depression and Anxiety",
title = "Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study",
volume = "32",
number = "6",
pages = "426-436",
doi = "10.1002/da.22352"
}

Lupattelli, A., Spigset, O., Bjoernsdottir, I., Haemeen-Anttila, K., Mardby, A., Panchaud, A., Juraski, R. G., Rudolf, G., Odalović, M., Drozd, M., Twigg, M. J., Juch, H., Moretti, M. E., Kennedy, D., Rieutord, A., Zagorodnikova, K., Passier, A.,& Nordeng, H.. (2015). Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study. in Depression and Anxiety
Wiley, Hoboken., 32(6), 426-436.
https://doi.org/10.1002/da.22352

Lupattelli A, Spigset O, Bjoernsdottir I, Haemeen-Anttila K, Mardby A, Panchaud A, Juraski RG, Rudolf G, Odalović M, Drozd M, Twigg MJ, Juch H, Moretti ME, Kennedy D, Rieutord A, Zagorodnikova K, Passier A, Nordeng H. Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study. in Depression and Anxiety. 2015;32(6):426-436.
doi:10.1002/da.22352 .

Lupattelli, Angela, Spigset, Olav, Bjoernsdottir, Ingunn, Haemeen-Anttila, Katri, Mardby, Ann-Charlotte, Panchaud, Alice, Juraski, Romana Gjergja, Rudolf, Gorazd, Odalović, Marina, Drozd, Mariola, Twigg, Michael J., Juch, Herbert, Moretti, Myla E., Kennedy, Debra, Rieutord, Andre, Zagorodnikova, Ksenia, Passier, Anneke, Nordeng, Hedvig, "Patterns and factors associated with low adherence to psychotropic medications during pregnancy - A cross-sectional, multinational web-based study" in Depression and Anxiety, 32, no. 6 (2015):426-436,
https://doi.org/10.1002/da.22352 . .

TY  - JOUR
AU  - Lupattelli, Angela
AU  - Spigset, Olav
AU  - Twigg, Michael J.
AU  - Zagorodnikova, Ksenia
AU  - Mardby, Ann-Charlotte
AU  - Moretti, Myla E.
AU  - Drozd, Mariola
AU  - Panchaud, Alice
AU  - Haemeen-Anttila, Katri
AU  - Rieutord, Andre
AU  - Juraski, R. Gjergja
AU  - Odalović, Marina
AU  - Kennedy, Debra
AU  - Rudolf, Gorazd
AU  - Juch, Herbert
AU  - Passier, Anneke
AU  - Bjoernsdottir, Ingunn
AU  - Nordeng, Hedvig
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2154
AB  - Objectives Intercountry comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilised and indication for use. Design Cross-sectional, web-based study performed within the period from 1 October 2011 to 29 February 2012. Uniform collection of drug utilisation data was performed via an anonymous online questionnaire. Setting Multinational study in Europe (Western, Northern and Eastern), North and South America and Australia. Participants Pregnant women and new mothers with children less than 1year of age. Primary and secondary outcome measures Prevalence of and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use. Results The study population included 9459 women, of which 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (adjusted OR (aOR): 0.55, 95% CI 0.34 to 0.87) and Northern Europe (aOR: 0.50, 95% CI 0.31 to 0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than non-immigrants. Conclusions In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.
PB  - BMJ PUBLISHING GROUP, LONDON
T2  - BMJ Open
T1  - Medication use in pregnancy: a cross-sectional, multinational web-based study
VL  - 4
IS  - 2
DO  - 10.1136/bmjopen-2013-004365
ER  - 

@article{
author = "Lupattelli, Angela and Spigset, Olav and Twigg, Michael J. and Zagorodnikova, Ksenia and Mardby, Ann-Charlotte and Moretti, Myla E. and Drozd, Mariola and Panchaud, Alice and Haemeen-Anttila, Katri and Rieutord, Andre and Juraski, R. Gjergja and Odalović, Marina and Kennedy, Debra and Rudolf, Gorazd and Juch, Herbert and Passier, Anneke and Bjoernsdottir, Ingunn and Nordeng, Hedvig",
year = "2014",
abstract = "Objectives Intercountry comparability between studies on medication use in pregnancy is difficult due to dissimilarities in study design and methodology. This study aimed to examine patterns and factors associated with medications use in pregnancy from a multinational perspective, with emphasis on type of medication utilised and indication for use. Design Cross-sectional, web-based study performed within the period from 1 October 2011 to 29 February 2012. Uniform collection of drug utilisation data was performed via an anonymous online questionnaire. Setting Multinational study in Europe (Western, Northern and Eastern), North and South America and Australia. Participants Pregnant women and new mothers with children less than 1year of age. Primary and secondary outcome measures Prevalence of and factors associated with medication use for acute/short-term illnesses, chronic/long-term disorders and over-the-counter (OTC) medication use. Results The study population included 9459 women, of which 81.2% reported use of at least one medication (prescribed or OTC) during pregnancy. Overall, OTC medication use occurred in 66.9% of the pregnancies, whereas 68.4% and 17% of women reported use of at least one medication for treatment of acute/short-term illnesses and chronic/long-term disorders, respectively. The extent of self-reported medicated illnesses and types of medication used by indication varied across regions, especially in relation to urinary tract infections, depression or OTC nasal sprays. Women with higher age or lower educational level, housewives or women with an unplanned pregnancy were those most often reporting use of medication for chronic/long-term disorders. Immigrant women in Western (adjusted OR (aOR): 0.55, 95% CI 0.34 to 0.87) and Northern Europe (aOR: 0.50, 95% CI 0.31 to 0.83) were less likely to report use of medication for chronic/long-term disorders during pregnancy than non-immigrants. Conclusions In this study, the majority of women in Europe, North America, South America and Australia used at least one medication during pregnancy. There was a substantial inter-region variability in the types of medication used.",
publisher = "BMJ PUBLISHING GROUP, LONDON",
journal = "BMJ Open",
title = "Medication use in pregnancy: a cross-sectional, multinational web-based study",
volume = "4",
number = "2",
doi = "10.1136/bmjopen-2013-004365"
}

Lupattelli, A., Spigset, O., Twigg, M. J., Zagorodnikova, K., Mardby, A., Moretti, M. E., Drozd, M., Panchaud, A., Haemeen-Anttila, K., Rieutord, A., Juraski, R. G., Odalović, M., Kennedy, D., Rudolf, G., Juch, H., Passier, A., Bjoernsdottir, I.,& Nordeng, H.. (2014). Medication use in pregnancy: a cross-sectional, multinational web-based study. in BMJ Open
BMJ PUBLISHING GROUP, LONDON., 4(2).
https://doi.org/10.1136/bmjopen-2013-004365

Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mardby A, Moretti ME, Drozd M, Panchaud A, Haemeen-Anttila K, Rieutord A, Juraski RG, Odalović M, Kennedy D, Rudolf G, Juch H, Passier A, Bjoernsdottir I, Nordeng H. Medication use in pregnancy: a cross-sectional, multinational web-based study. in BMJ Open. 2014;4(2).
doi:10.1136/bmjopen-2013-004365 .

Lupattelli, Angela, Spigset, Olav, Twigg, Michael J., Zagorodnikova, Ksenia, Mardby, Ann-Charlotte, Moretti, Myla E., Drozd, Mariola, Panchaud, Alice, Haemeen-Anttila, Katri, Rieutord, Andre, Juraski, R. Gjergja, Odalović, Marina, Kennedy, Debra, Rudolf, Gorazd, Juch, Herbert, Passier, Anneke, Bjoernsdottir, Ingunn, Nordeng, Hedvig, "Medication use in pregnancy: a cross-sectional, multinational web-based study" in BMJ Open, 4, no. 2 (2014),
https://doi.org/10.1136/bmjopen-2013-004365 . .

TY  - CONF
AU  - Lupattelli, Angela
AU  - Spigset, Olav
AU  - Twigg, Michael J.
AU  - Zagorodnikova, Ksenia
AU  - Mardby, Ann-Charlotte
AU  - Moretti, Myla E.
AU  - Drozd, Mariola
AU  - Panchaud, Alice
AU  - Haemeen-Anttila, Katri
AU  - Rieutord, Andre
AU  - Gjergia, Romana
AU  - Odalović, Marina
AU  - Kennedy, Debra
AU  - Rudolf, Gorazd
AU  - Juch, Herbert
AU  - Passier, Anneke
AU  - Bjoernsdottir, Ingunn
AU  - Nordeng, Hedvig
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1892
PB  - John Wiley & Sons, Ltd
C3  - Pharmacoepidemiology and Drug Safety
T1  - Medication Use during Pregnancy: A Multinational Perspective
VL  - 22
IS  - s1
SP  - 75
EP  - 75
DO  - 10.1002/pds.3512
ER  - 

@conference{
author = "Lupattelli, Angela and Spigset, Olav and Twigg, Michael J. and Zagorodnikova, Ksenia and Mardby, Ann-Charlotte and Moretti, Myla E. and Drozd, Mariola and Panchaud, Alice and Haemeen-Anttila, Katri and Rieutord, Andre and Gjergia, Romana and Odalović, Marina and Kennedy, Debra and Rudolf, Gorazd and Juch, Herbert and Passier, Anneke and Bjoernsdottir, Ingunn and Nordeng, Hedvig",
year = "2013",
publisher = "John Wiley & Sons, Ltd",
journal = "Pharmacoepidemiology and Drug Safety",
title = "Medication Use during Pregnancy: A Multinational Perspective",
volume = "22",
number = "s1",
pages = "75-75",
doi = "10.1002/pds.3512"
}

Lupattelli, A., Spigset, O., Twigg, M. J., Zagorodnikova, K., Mardby, A., Moretti, M. E., Drozd, M., Panchaud, A., Haemeen-Anttila, K., Rieutord, A., Gjergia, R., Odalović, M., Kennedy, D., Rudolf, G., Juch, H., Passier, A., Bjoernsdottir, I.,& Nordeng, H.. (2013). Medication Use during Pregnancy: A Multinational Perspective. in Pharmacoepidemiology and Drug Safety
John Wiley & Sons, Ltd., 22(s1), 75-75.
https://doi.org/10.1002/pds.3512

Lupattelli A, Spigset O, Twigg MJ, Zagorodnikova K, Mardby A, Moretti ME, Drozd M, Panchaud A, Haemeen-Anttila K, Rieutord A, Gjergia R, Odalović M, Kennedy D, Rudolf G, Juch H, Passier A, Bjoernsdottir I, Nordeng H. Medication Use during Pregnancy: A Multinational Perspective. in Pharmacoepidemiology and Drug Safety. 2013;22(s1):75-75.
doi:10.1002/pds.3512 .

Lupattelli, Angela, Spigset, Olav, Twigg, Michael J., Zagorodnikova, Ksenia, Mardby, Ann-Charlotte, Moretti, Myla E., Drozd, Mariola, Panchaud, Alice, Haemeen-Anttila, Katri, Rieutord, Andre, Gjergia, Romana, Odalović, Marina, Kennedy, Debra, Rudolf, Gorazd, Juch, Herbert, Passier, Anneke, Bjoernsdottir, Ingunn, Nordeng, Hedvig, "Medication Use during Pregnancy: A Multinational Perspective" in Pharmacoepidemiology and Drug Safety, 22, no. s1 (2013):75-75,
https://doi.org/10.1002/pds.3512 . .